Cloudera Launches Private Link Network for Secure, Internet-Free Cloud Connectivity

 Dubai, United Arab Emirates 

New updates address growing data demands for industries with stringent compliance requirements

Cloudera, the only true hybrid platform for data, analytics and AI, today launched the Cloudera Private Link Network to address critical data security and privacy concerns for highly regulated organizations with strict internal data security policies. Cloudera Private Link Network provides secure, private connectivity from customer workloads to the Cloudera Control Plane, ensuring that data does not traverse the public Internet.

 

Organizations in industries such as finance, healthcare, and pharmaceuticals often face privacy challenges because providers often cannot guarantee that traffic between tenants, even within the same cloud, will not traverse the Internet and risk data exposure. Cloudera Private Link Network helps to solve these challenges by providing a unified, cross-cloud private connectivity service, enabling enterprises to securely manage data-intensive workloads across multiple cloud environments through a single, specialized network.

 

Cloudera Private Link Network integrates across major cloud providers by utilizing existing cloud provider services like AWS PrivateLink and Azure Private Link and other network infrastructure such as multi-cloud connectivity. This setup extends secure data transfer across multiple cloud environments, to enable consistent security and streamlined management. Customers can efficiently self-serve and provision services using the Cloudera Command Line Interface.

 

“Cloudera Private Link Network is purpose-built and managed by Cloudera to address enterprise privacy and connectivity concerns. By offloading the management of Private Link Network to Cloudera, it will both lower TCO for your organization and free up valuable resources, allowing you to focus on strategic business initiatives,” said Dipto Chakravarty, Chief Product Officer at Cloudera. “By managing  data integrity and trustworthiness throughout the architecture, we help enterprises safeguard sensitive customer data.”

 

“As organizations move to cross-cloud deployments, they expect to drastically reduce the complexity of multi-platform configurations to a point that they should only have to specify private link network endpoints between their control plane and the data planes,” said industry analyst, Sanjeev Mohan. “Private Link Network helps enterprises protect their data more effectively and easily leverage disparate clouds to reduce total cost of ownership. This advancement further establishes Cloudera as a leader in providing secure, cross-cloud connectivity for metadata management.”

 

Cloudera Private Link Network will be on display at Cloudera EVOLVE Dubai, taking place September 12, 2024, at the Museum of the Future. Attendees will see the power of Cloudera Private Link Network firsthand and gain insights into the real-world experiences of leading-edge companies from around the globe.

 

For more information on how Cloudera Private Link Network addresses the growing need for secure, private data connectivity across increasingly complex multi-cloud environments, visit our recent blog.

 

About Cloudera

 

Cloudera is the only true hybrid platform for data, analytics, and AI. With 100x more data under management than other cloud-only vendors, Cloudera empowers global enterprises to transform data of all types, on any public or private cloud, into valuable, trusted insights. Our open data lakehouse delivers scalable and secure data management with portable cloud-native analytics, enabling customers to bring GenAI models to their data while maintaining privacy and ensuring responsible, reliable AI deployments. The world’s largest brands in financial services, insurance, media, manufacturing, and government rely on Cloudera to use their data to solve what once seemed impossible—today and in the future.

 

To learn more, visit Cloudera.com and follow us on LinkedIn and X. Cloudera and associated marks are trademarks or registered trademarks of Cloudera, Inc. All other company and product names may be trademarks of their respective owners.

Permalink

https://www.aetoswire.com/en/news/1309202441404

Contacts

Melwyn Abraham - melwyn@matrixdubai.com

MicroVention Rebrands to Terumo Neuro – Reflects Expanded Focus and Strategic Growth

 (BUSINESS WIRE) -- MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.

Founded in 1997 and acquired by Terumo Corporation in 2006, MicroVention has been at the forefront of developing technologies that support neurovascular surgeons in preserving and restoring brain health. As Terumo Neuro, the company is poised to continue its legacy of innovation with an enhanced focus on driving impactful growth and leveraging Terumo’s global resources and reputation.

Carsten Schroeder, President and CEO of Terumo Neuro, commented on the rebranding: "This transformation reflects our growth as a company and Terumo's confidence in our future. For eighteen years, we have maintained independent branding as MicroVention, and now, as Terumo Neuro, we’re combining the best of MicroVention with the full strength and support of the Terumo family. Our culture, speed of innovation, focus on game-changing technologies, and close collaboration with physicians will remain unchanged."

He continued, "What will evolve is a deeper partnership with Terumo, a new visual brand, and a more defined brand identity under our new name and slogan, ‘Terumo Neuro: Game-changing Impact.’ Our strategy is expanding beyond our core focus on hemorrhagic and ischemic stroke and access solutions to encompass the neurovascular patient care continuum."

As Terumo Neuro, the company will continue its close collaboration with leading physicians worldwide, translating clinical insights into technologies that enhance patient outcomes. Schroeder emphasized that the company’s DNA remains rooted in innovation for ischemic stroke, hemorrhagic stroke, and access, while expanding into broader areas of neurovascular care.

About Terumo Neuro (Formerly MicroVention, Inc.)

We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912077658/en/

Permalink

https://www.aetoswire.com/en/news/1309202441387

Contacts

Media Contact:

Christine McCullough

Global Corporate Communications

Terumo Neuro

+ 1 714 206 9800

christine.mccullough@microvention.com

Brightcove Unveils the ‘Brightcove AI Suite’ with Solutions to Supercharge Content Creation, Engagement and Revenue

 BOSTON - 

The new AI suite is integrated into Brightcove’s award-winning video cloud platform to deliver customer ROI through expanded content creation, deeper engagement, increased revenue, and enhanced cost-to-quality efficiency

The Brightcove AI Suite leverages Generative AI models from Anthropic, AWS, and Google

(BUSINESS WIRE) -- Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced the introduction of the Brightcove AI Suite, a multi-faceted product launch designed to shape the future of video and engagement technology. The new AI-powered capabilities, developed in collaboration with customers, will address their growth-driving and cost-saving needs, including content creation, audience growth and engagement, increased revenue, and improved business efficiency.

“Generative AI is transforming how companies create content and how users engage, and we believe it will drive a boom in video content and its consumption. To enable our customers to take full advantage of these next-generation creation and engagement capabilities, we are enhancing our platform with a suite of AI-driven solutions to deliver on these opportunities,” said Marc DeBevoise, CEO of Brightcove. “By listening to our customers and analyzing their businesses and use cases, we built the Brightcove AI Suite to address their needs, especially in key focus areas, including maximizing content utilization, driving engagement, growing revenue, and solving the cost-to-quality equation.”

Building on 20 years at the forefront of video technology and engagement, the Brightcove AI Suite will integrate seamlessly into Brightcove’s two-time Emmy Award-winning video cloud platform and customer experiences so companies can optimize and accelerate their video content strategy and processes, all within the platform. The Brightcove AI Suite will launch with five new AI-powered solutions: AI Content Multiplier, AI Universal Translator, AI Metadata Optimizer, AI Engagement Maximizer, and AI Cost-to-Quality Optimizer. Each solution is available to existing customers to pilot, with general availability planned for later this year. These solutions will help customers create and optimize content, grow engagement and monetization, and reduce the costs of creating, managing, and delivering content without sacrificing quality.

As part of this initiative, Brightcove is strengthening its platform by using models from industry leaders like Anthropic, AWS, and Google to deliver excellence and speed of innovation by adding the power of their Generative AI models to Brightcove’s solutions. Additionally, Brightcove is integrating AI solutions from other partners, including CaptionHub and Frammer.

The Brightcove AI Suite will initially focus on solutions in four key areas that Brightcove customers shared as their most significant priorities and business needs. The solutions within these areas are designed to accelerate customers’ engagement and video AI capabilities across industries and use cases. The four priority areas are:

Content Creation: These generative solutions will help customers breathe new life into existing content libraries by enabling the creation of more videos quickly and easily to engage audiences. Solutions within this area include the AI Content Multiplier, which uses Gen AI to automate time-consuming tasks within the platform through actions like reformatting horizontal to vertical content, auto-clipping, auto-summarization, and creating highlight reels from longer content, and the AI Universal Translator, which will allow companies to deliver accurate translations across 130 languages with the ability to fine-tune, plus dubbing in over 80 languages and hundreds of voices with the ability to edit pronunciations and timing.

Content Management and Optimization: These solutions will help customers accelerate workflows and significantly simplify managing content libraries. This includes turning content libraries into a foundational data layer and optimizing those libraries for large language models (LLMs) to improve discoverability and engagement. As part of this effort, Brightcove is launching an AI Metadata Optimizer, which will generate descriptions and automatically transform content into searchable and AI-optimizable data sets to help make it more discoverable and monetizable. This solution will minimize the task of sorting through hundreds of hours of content by hand and adding necessary descriptors and tags.

Content Engagement and Monetization: These solutions are designed to help customers seeking to exceed their growth and revenue goals by finding the best ways to maximize their content's engagement and revenue. As part of this, the Brightcove AI Engagement Maximizer will deliver new capabilities like AI-powered automated video interactivity, personalization, and recommendations to deeply engage audiences and build loyalty. Brightcove is also working on an industry-transforming AI Revenue Maximizer solution that will optimize ad placements and durations to automatically maximize revenue without impacting viewer satisfaction.

Quality and Efficiency: These solutions will help customers manage costs without compromising quality. With Brightcove’s AI Cost-to-Quality Optimizer, companies can drive down the cost of encoding, storage, and content delivery without sacrificing the viewer experience. The solution will continuously optimize content ingestion and delivery by using a combination of Brightcove’s Emmy Award-winning Context Aware Encoding (CAE) technology, market-leading delivery engine, and Quality of Experience (QoE) insights benchmarks. These will work in tandem to manage costs automatically for a company based on their choice of quality levels.

The Brightcove AI Suite is a collaborative, customer-focused initiative being tested with more than a dozen customers, including Management Leadership for Tomorrow (MLT), Major League Fishing, Italiaonline, and OneValley. For a limited time, the company is expanding its AI pilot program to all customers at no additional cost.

“As a trusted partner to more than 2,000 global customers, we are also launching the Brightcove AI Pledge: a commitment to securely handling customer data with transparency and responsibility,” said Scott Levine, Chief Product Officer at Brightcove. “Part of our differentiation will be our ability to advance Generative AI securely, protecting our customers' most valuable assets, including transparent guiding principles to protect customer data and content integrity. We will only use data and content to train our AI models with explicit permission from our customers so they can decide their level of inclusion and security.”

Brightcove is committed to building the world’s smartest, fastest, and most reliable automated engagement platform, anchored in video, to revolutionize how customers engage and grow their audience, increase revenue, and improve business efficiency. The Brightcove AI Suite will continue to launch new capabilities in the near and long term based on customer feedback and use.

For more information about becoming a pilot customer, visit Brightcove.com.

About Brightcove Inc.

Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X, Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912834356/en/

Permalink

https://www.aetoswire.com/en/news/1209202441381

Contacts

MEDIA CONTACT

Joseph J. Nuñez

Director of Global Communications and Public Relations

jnunez@brightcove.com

 

Eaton Expands Commercial Vehicle Transmission Portfolio Across the Powertrain Spectrum

 HANOVER, Germany - Thursday, 12. September 2024

(BUSINESS WIRE)--Intelligent power management company Eaton today announced it will be displaying a number of transmissions for both traditional and electrified commercial vehicles at IAA Transportation, September 17–22, in Hanover, Germany.

New automated manual transmissions for internal combustion-powered buses and trucks

Introduced earlier this year to the Brazilian market, the new Advantor™ series of automated manual transmissions (AMTs) are designed for commercial vehicles with internal combustion engines (ICEs). Advantor AMTs leverage Eaton’s long history of innovation and reliability in automated transmission technology.

“The Advantor series has many product features that bus and truck manufactures globally will find attractive, particularly in emerging markets such as South America and Asia-Pacific regions,” said Marcos Janasi, business unit director, Commercial Powertrain, Eaton’s Mobility Group. “Our new transmission series is designed to deliver significant fuel efficiency and enhanced performance across a variety of vehicle duty cycles, and to provide reliability and ease of service.”

Several versions of the Advantor AMT will be available in the next 24 months, including the Advantor-6, which was developed for the light-duty truck and bus segment; the Advantor-8, which targets the medium-duty bus market; and other versions to meet the needs of the broader commercial truck market. The Advantor series leverages common components to reduce complexity, improve serviceability, and to deliver a better driving experience.

Central drive transmission solutions for electrified vehicles

Eaton will also showcase its central drive transmission solutions, which are designed to be compatible with any electric motor/inverter/battery system and to be used in central drive applications, where the electric motor and transmission are in the traditional location in the vehicle. Eaton’s medium- and heavy-duty versions of its 4-speed EV automated transmission deliver superior performance on grades and acceleration for electric commercial vehicles while offering more flexible gear ratios compared to competitive technologies. The compact architecture is designed to improve system efficiency, enabling longer vehicle range and battery life.

Eaton’s heavy-duty 4-speed transmission was recently recognized as a 2024 Automotive News PACEpilot Innovation to Watch and is currently in production.

Ultra-compact EV transmission provides increase torque, payload

Rounding out the portfolio is Eaton’s innovative ultra-compact ​4-speed EV transmission, which offers a substantial increase in torque density,​ unlocking increased payload​, extended range, more packaging availability for batteries​, and flexible configurations.

Learn more about Eaton’s commercial vehicle transmissions or visit Hall 21, Booth B22 at IAA Transportation 2024.

Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.

Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912318482/en/

Permalink

https://www.aetoswire.com/en/news/1209202441374

Contacts

Thomas Nellenbach

(216) 333-2876 (cell)

thomasjnellenbach@eaton.com

 

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair

  CHESTERBROOK, Pa. - Thursday, 12. September 2024 AETOSWire 

– Breakthrough Therapy designation for NTX-001 granted by FDA

– Preparation is underway for the Phase 3 program to begin in early 2025

(BUSINESS WIRE) -- Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking therapy in the field of nerve repair.

Neuraptive is preparing to launch a Phase 3 pivotal program for NTX-001 in early 2025. The program will consist of a single randomized, double-blind, placebo-controlled study assessing the efficacy and safety of NTX-001 in patients with peripheral nerve injury requiring repair. The final protocol for this single Phase 3 study is currently being discussed with the FDA. This follows the promising results from the Phase 2 NEUROFUSE study after 24 weeks. Neuraptive anticipates the full results, including all 48 weeks of data, to be available in the coming weeks and will look to share the results at an upcoming scientific conference.

“The FDA’s Breakthrough Therapy designation for NTX-001 is a major step forward in our mission to provide an innovative treatment for patients suffering from peripheral nerve injuries requiring repair,” said Evan L. Tzanis, COO and EVP of R&D at Neuraptive Therapeutics. “We are eager to continue working closely with the FDA to ensure NTX-001 reaches patients as quickly as possible and to deliver a transformative therapy in the field of nerve repair. We are grateful to the patients, investigators, and our partners who have remained committed to advancing NTX-001.”

With the continued advancement of NTX-001, Neuraptive Therapeutics, Inc., remains at the forefront of developing novel solutions for a significant number of patients affected by peripheral nerve injuries globally.

About Neuraptive Therapeutics, Inc.

Neuraptive Therapeutics, Inc. is dedicated to the innovation and development of medical products and therapeutics to repair and regenerate peripheral nerves. The company is focused on addressing the unmet medical needs of patients and physicians dealing with the complex challenges of nerve injuries.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements subject to various risks and uncertainties. Actual results could materially differ from those anticipated in the forward-looking statements due to various factors. Neuraptive Therapeutics, Inc. disclaims any obligation to update the information contained in these forward-looking statements.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240911372663/en/

Permalink

https://www.aetoswire.com/en/news/1209202441362

Contacts

For more information about the NEUROFUSE Study or to inquire about Neuraptive Therapeutics, Inc.:

IR@neuraptive.com

+1-484-787-3203

 

Merck Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity

 DARMSTADT, Germany 

Phase IV studies demonstrate the consistent safety and high efficacy of MAVENCLAD on NEDA-3, MRI and cognition outcomes over four years

New data on blood and CSF biomarkers show the impact of MAVENCLAD to promote immune cell reconstitution, while clinical data confirmed 93.7% of patients free from PIRA

MAVENCLAD has now treated more than 100,000 patients globally, underscoring its trusted efficacy and safety profile

(BUSINESS WIRE) -- Not intended for UK-, US- or Canada-based media

Merck, a leading science and technology company, today announced presentations showcasing the long-term safety profile, sustained efficacy data, and durable effect of MAVENCLAD® (cladribine tablets) in individuals with relapsing multiple sclerosis (RMS). Among 34 total MAVENCLAD presentations are data from several MAGNIFY-MS sub-studies demonstrating the impact of MAVENCLAD on disability progression, central inflammation, and an oral presentation on immune reconstitution effects. These data, along with six other company abstracts, will be presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place September 18-20 in Copenhagen.

“The efficacy of MAVENCLAD has long been established through traditional endpoints from our original pivotal trials and beyond. Now, with additional measures of the impact on neuroinflammation and progression, we can reaffirm and further solidify its long-term efficacy position within the MS treatment landscape,” said Alexander Kulla, Senior Vice President & Medical Unit Head Neurology & Immunology at Merck. “MAVENCLAD continues to demonstrate its consistent safety profile with sustained benefits, impacting the lives of more than 100,000 people living with MS."

Results from the MAGNIFY-MS extension, a Phase IV study evaluating patients (n=219) on MAVENCLAD with highly active RMS, confirmed 79.2% of patients achieved no evidence of disease activity (NEDA-3) during Year 4 of the treatment. The annualized relapse rate (ARR) remained low overall (0.09) and was further reduced (0.06) in treatment-naïve patients over four years. Similarly, the CLARIFY-MS extension showed the sustained benefits in MAVENCLAD-treated patients (n=280) on cognition, in addition to MRI outcomes and relapses, four years after the initial treatment dose. Specific to cognition, 77.5% of patients had improved or stable scores at four years, based on the 8-point cut-off of the Symbol Digit Modalities Test (SDMT). In both studies, safety data aligned with the established profile from clinical trials.

Two-year data from a MAGNIFY-MS sub-study found patients with highly active RMS treated with MAVENCLAD had low overall disability accrual, including low rates of progression independent of relapse activity (PIRA). At two years, rates for all disability measures were low overall with 93.7% of patients free from PIRA. The reduction of PIRA is especially notable in treatment-naïve patients (3.4% vs 8.5% in treatment-experienced patients), emphasizing the benefits of early treatment initiation with MAVENCLAD. Overall, these data suggest that MAVENCLAD is likely to preserve the physical abilities and prevent relapses in individuals with RMS, supporting the sustained efficacy and durable effect of MAVENCLAD.

Building on prior data, which showed MAVENCLAD reduces or eliminates oligoclonal bands in the cerebrospinal fluid (CSF), new two-year data demonstrate reductions in gene expression and protein levels of markers associated with inflammation, including pro-inflammatory cytokines, providing insights into the potential multifaceted effect of MAVENCLAD in the peripheral blood and CSF. This data suggests that immune reconstitution following treatment with cladribine tablets may shift the immune system to a less pathogenic state. Analyses of CSF proteomics and T and B cell transcriptomics further substantiate the clinical findings, suggesting the potential of MAVENCLAD to reduce disease activity and progression in RMS patients.

To view our 40 accepted abstracts and posters to be presented from across our MS portfolio at ECTRIMS, including innovative analyses of MAVENCLAD using artificial intelligence, please visit the Programme.

About MAVENCLAD®

MAVENCLAD, approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019, is the first and only short-course oral therapy for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis (MS), and MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS). Patients should follow healthcare provider instructions including cancer screening, contraception and blood tests. The approved dose of MAVENCLAD is 3.5 mg per kg body weight over two years, administered as one treatment course of 1.75 mg per kg per year, each consisting of two treatment weeks. The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes. MAVENCLAD causes a dose-dependent reduction in lymphocyte counts followed by recovery.

Because cladribine is cytotoxic, special handling and disposal instructions should be followed.

More than 100,000 patients have been treated with MAVENCLAD since its launch in 2019. MAVENCLAD has been approved in over 80 countries, including the European Union (EU), Canada, Australia and Switzerland, for various relapsing MS indications. Visit www.MAVENCLAD.com for more information.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.8 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

Merck in Neurology and Immunology

Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company’s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG).

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of €21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912822668/en/

Permalink

https://www.aetoswire.com/en/news/1209202441377

Contacts

Media Relations

Flavia.felix@emdserono.com

Phone: +1 781 427 1892

International Real Estate Group Rebrands as Accumin to Empower Better Property Decisions

 MADRID - Thursday, 12. September 2024 

Asertia, the international real estate group behind market leaders Tinsa and Deyde DataCentric (Spain and Latin America); Persch Consult and on-geo (Germany); and Troostwijk (Netherlands), among others, unites its companies under a new group name: Accumin.

This strategic move brings together more than 1,500 employees from more than 20 companies in 14 countries, across 3 continents with a commitment to help their clients make the right Real Estate decisions.

Accumin offers global independent expertise combined with innovative software solutions and actionable intelligence that will help its clients and their customers See Value Clearly.

 

(BUSINESS WIRE) -- Asertia, owned by international private equity firm Cinven, has announced plans to reorganise and define more clearly its diverse range of products and services around the globe under a new brand – Accumin.

As one of the world’s largest and most trusted real estate advisory companies with more than 40 years of experience, Accumin has one clear purpose: to empower people and businesses to grow by making the right Real Estate decisions and See Value Clearly. As part of redefining the group, Asertia combines its collective products and services under three core verticals to bring greater clarity on the group’s capabilities: Value & Advisory, Intelligence & Software, and Risk Management. In addition to the three verticals, there will also be a new division called Home, which will primarily focus on bringing greater clarity and efficiency to help consumers make better real estate decisions as buyers, sellers and owners of real estate.

“Value is everywhere if you know how to look. In a world that is increasingly uncertain, our aim is to bring precision, clarity and innovation, and build trust with our clients, identifying opportunities and risks that might otherwise go unnoticed. This is an exciting phase of our present and future evolution as a combined group that demonstrates our overall capabilities in independent expertise and innovative intelligence and software solutions. Our purpose is to help our clients and their customers see value clearly, building upon our reputation as a company that clients can trust to provide them quality and independent, unbiased advice,” said James Cornell, Global CEO of Accumin.

To strengthen the company’s strategic global vision, Accumin has named experts to lead its newly defined structure:

Maarten de Hass has recently joined as the Global Head of Value & Advisory. Maarten has significant international Real Estate experience in multinational companies and brings with him years of working in consulting firms such as MVGM, Cushman, Deloitte and EY.

Manuel Hurtado also recently joined as the Global Head of Intelligence. Coming from the strategy and technology consulting firm McKinsey, Manuel has been a key leader in their data and Gen AI area and has more than a decade of international experience in data strategy, digital transformation and analytics.

Johan Drost, current CEO of Troostwijk Group, a subsidiary of Accumin, has been appointed Global Head of Risk Management. Here Johan combines his background within banking and insurance to help build on Troostwijk’s vast products and services from risk inspection to Real estate loss assessing and valuation for insurance purposes.

Jose Rivera, current Group Head of Digital will lead the transversal, and newly created consumer-focused division and become Global Head of Accumin Home.

“Our strength and our value lie in our integration of independent diverse perspectives from various countries, sectors, and disciplines, which gives us a global vision backed by local expertise, strengthening our ability to cut through complexity, providing value and clarity to our business customers and to the end consumer,” adds Cornell. “By amplifying our human perspective with intelligence and software, we give clients greater control and confidence over Real Estate related decisions, which is what will be key to helping our clients and their customers see value clearly.”

Today’s repositioning of the group under the global brand of Accumin is the beginning of a wider unification in how the company presents itself, working together whilst respecting regulation to preserve independence and data protection between its subsidiaries. While the company envisions most of its companies to ultimately rebrand as Accumin, most subsidiaries will first pass through a transition period in which they will be endorsed “by Accumin” to respect the powerful reputation that the individual companies have built in their local markets.

As the group unites as one, Accumin transforms into an ecosystem of local and global expertise, harnessing the power of the diversity of its talent supported by intelligence and software, true to its name: the combination of knowledge, or acumen, and accuracy or precision, which are central to the value proposition the company offers for clients.

About Accumin

Accumin is one of the world’s largest and most trusted independent real estate groups, offering diverse, global expertise in a powerful and innovative portfolio of tech-enabled solutions for real estate and property management backed by decades of experience. With innovative and complementary solutions for Value & Advisory, Intelligence & Software, and Risk Management, and an approach based on precision, independence and clarity, Accumin aims to help corporate clients and end consumers navigate uncertainty and make the right decisions.

With more than 1,500 employees in 14 countries across Europe, Latin America and Africa, and deep technical and local knowledge, Accumin has a clear commitment: to cut through complexity and help clients See Value Clearly.

Learn more about Accumin at www.accumin.com.

About Cinven

Cinven is a leading international private equity firm focused on building world-class global and European companies. Its funds invest in six key sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials and Technology, Media and Telecommunications (TMT). Cinven has offices in London, New York, Frankfurt, Paris, Milan, Madrid, Guernsey and Luxembourg.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912996582/en/

Permalink

https://aetoswire.com/en/news/1209202441369

Contacts

Accumin Global Communications

communications@accumin.com